**Appendix 4a: Interaction models to assess preferences by age and level of education**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Age** | | | **Education** | | |
|  | β | SE | CI 95% | β | SE | CI 95% |
| Constant | 0.569\*\*\* | 0.139 | 0.297,0.841 | 0.584\*\*\* | 0.139 | 0.312,0.855 |
| Out-of-pocket payment | -0.46x10-4\*\*\* | 0.1x10-4 | -0.67x10-4,-0.26x10-4 | -0.59x10-4\*\*\* | 0.11x10-4 | -0.81x10-4, -0.37x10-4 |
| Progression free survival (PFS) | 0.028\*\*\* | 0.005 | 0.017,0.038 | 0.019\*\*\* | 0.005 | 0.010,0.028 |
| Febrile neutropenia (FN) | -0.025\*\*\* | 0.006 | -0.036,-0.014 | -0.043\*\*\* | 0.006 | -0.056,-0.031 |
| No pain (reference: severe pain) | 0.571\*\*\* | 0.062 | 0.450,0.693 | 0.726\*\*\* | 0.066 | 0.596,0.856 |
| Moderate pain (reference: severe pain) | 0.480\*\*\* | 0.066 | 0.351,0.609 | 0.368\* | 0.170 | 0.035,0.701 |
| No impairment functional wellbeing (reference: severely impaired) | 0.704\*\*\* | 0.076 | 0.554,0.853 | 0.794\*\*\* | 0.074 | 0.648,0.940 |
| Moderate impairment functional wellbeing (reference: severely impaired) | 0.604\*\*\* | 0.059 | 0.488,0.719 | 0.746\*\*\* | 0.065 | 0.619,0.873 |
| **Interaction variables:**  **Subgroup \* Attribute level** | Age <54 = 0, Age>54 =1 | | | No higher education =0, Higher education =1 | | |
| Out-of-pocket payment | -0.4x10-5 | 0.17x10-4 | -0.38x10-4,  0.30x10-4 | 0.2x10-4 | 0.17x10-4 | -0.10x10-4,  0.58x10-4 |
| Progression free survival (PFS) | 0.296x10-5 | 0.009 | -0.018,0.018 | 0.020\* | 0.009 | 0.002,0.038 |
| Febrile neutropenia (FN) | -0.024\*\* | 0.009 | -0.041,-0.006 | 0.016 | 0.009 | -0.971x10-3,  0.033 |
| No pain (reference: severe pain) | 0.376\*\*\* | 0.113 | 0.156,0.597 | 0.012 | 0.102 | -0.187,0.211 |
| Moderate pain (reference: severe pain) | 0.213 | 0.117 | -0.016,0.442 | 0.041 | 0.033 | -0.024,0.106 |
| No impairment functional wellbeing (reference: severely impaired) | 0.305\*\* | 0.114 | 0.081,0.529 | 0.069 | 0.117 | -0.160,0.297 |
| Moderate impairment functional wellbeing (reference: severely impaired) | 0.323\*\* | 0.102 | 0.123,0.523 | -0.031 | 0.100 | -0.228,0.165 |
| Number of observations (N respondents) | **17808(371)** | | | **17616(367)** | | |
| chi-squared | **612.083** | | | **553.849** | | |
| Model degrees of freedom | **15** | | | **15** | | |
| Log likelihood | **-5232.701** | | | **-5177.216** | | |
| Pseudo-R-Squared | **0.198\*\*\*** | | | **0.197\*\*\*** | | |

\* p<0.05, \*\* p<0.01, \*\*\* p<0.001

**Appendix 4b: Interaction models to assess preferences by stage of cancer**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Localised | | | Advanced | | | Remission | | |
|  | β | SE | CI 95% | β | SE | CI 95% | b | se | ci95 |
| Constant | 0.581\*\*\* | 0.139 | 0.308,0.854 | 0.576\*\*\* | 0.138 | 0.305,0.847 | 0.571\*\*\* | 0.139 | 0.299,0.843 |
| Out-of-pocket payment | -0.55x10-4\*\*\* | 0.1x10-4 | -0.75x10-4,  -0.34x10-4 | -0.51x10-4\*\*\* | 0.8x10-5 | -0.67x10-4,  -0.35x10-4 | -0.31x10-4\* | 0.13x10-4 | -0.56x10-4,  -0.06x10-4 |
| Progression free survival (PFS) | 0.030\*\*\* | 0.005 | 0.020,0.040 | 0.028\*\*\* | 0.004 | 0.020,0.035 | 0.023\*\*\* | 0.006 | 0.011,0.035 |
| Febrile neutropenia (FN) | -0.040\*\*\* | 0.005 | -0.050,-0.030 | -0.038\*\*\* | 0.005 | -0.047,-0.028 | -0.020\*\* | 0.007 | -0.034,-0.006 |
| No pain (reference: severe pain) | 0.925\*\*\* | 0.068 | 0.792,1.057 | 0.706\*\*\* | 0.051 | 0.604,0.807 | 0.453\*\*\* | 0.070 | 0.317,0.589 |
| Moderate pain (reference: severe pain) | 0.697\*\*\* | 0.069 | 0.561,0.833 | 0.567\*\*\* | 0.054 | 0.463,0.672 | 0.361\*\*\* | 0.074 | 0.217,0.506 |
| No impairment functional wellbeing (reference: severely impaired) | 1.014\*\*\* | 0.072 | 0.873,1.155 | 0.814\*\*\* | 0.057 | 0.702,0.926 | 0.576\*\*\* | 0.087 | 0.406,0.746 |
| Moderate impairment functional wellbeing (reference: severely impaired) | 0.870\*\*\* | 0.064 | 0.746,0.996 | 0.722\*\*\* | 0.048 | 0.627,0.816 | 0.548\*\*\* | 0.069 | 0.413,0.683 |
| **Interaction variables:**  **Subgroup \* Attribute level** | localised=1, rest of stages=0 | | | advanced=1, rest of stages=0 | | | remission=1, rest of stages=0 | | |
| Out-of-pocket payment | 0.21x10-4 | 0.18x10-4 | -0.14x10-4,  0.55x10-4 | 0.39x10-4 | 0.36x10-4 | -0.32x10-4,  0.109x10-3 | -0.3x10-4 | 0.17x10-4 | -0.64x10-4,  0.03x10-4 |
| Progression free survival (PFS) | -0.008 | 0.009 | -0.025,0.010 | -0.714x10-3 | 0.016 | -0.032,0.0304 | 0.008 | 0.009 | -0.009,0.026 |
| Febrile neutropenia (FN) | 0.015 | 0.010 | -0.004,0.034 | 0.038\*\* | 0.012 | 0.013,0.063 | -0.027\*\* | 0.009 | -0.044,-0.009 |
| No pain (reference: severe pain) | -0.577\*\*\* | 0.104 | -0.781,-0.372 | 0.228 | 0.218 | -0.199,0.654 | 0.477\*\*\* | 0.105 | 0.271,0.683 |
| Moderate pain (reference: severe pain) | -0.370\*\* | 0.113 | -0.592,-0.147 | -0.028 | 0.190 | -0.401,0.344 | 0.365\*\* | 0.111 | 0.147,0.583 |
| No impairment functional wellbeing (reference: severely impaired) | -0.530\*\*\* | 0.116 | -0.757,-0.302 | 0.175 | 0.255 | -0.325,0.676 | 0.454\*\*\* | 0.115 | 0.229,0.679 |
| Moderate impairment functional wellbeing (reference: severely impaired) | -0.388\*\*\* | 0.096 | -0.575,-0.199 | 0.127 | 0.216 | -0.297,0.551 | 0.335\*\*\* | 0.097 | 0.144,0.526 |
| **Number of observations (N respondents)** | **17808(371)** | | | **17808(371)** | | | **17808(371)** | | |
| **chi-squared** | **624.114** | | | **579.182** | | | **679.588** | | |
| **Model degrees of freedom** | **15** | | | **15** | | | **15** | | |
| **Log likelihood** | **-5198.891** | | | **-5238.113** | | | **-5214.513** | | |
| **Pseudo-R-Squared** | **0.203\*\*\*** | | | **0.197\*\*\*** | | | **0.200\*\*\*** | | |

\* p<0.05, \*\* p<0.01, \*\*\* p<0.001